Vanda Pharmaceuticals rises after BLA for rare skin disease treatment

Shares of Vanda Pharmaceuticals VNDA.O rise 7.2% to $6.74

Co submits Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis (GPP), a rare and life-threatening inflammatory skin disease

Says BLA supported by positive data from late-stage GEMINI-1 and GEMINI-2 trials showing rapid and sustained disease clearance with favorable safety profile

Vanda requests priority review from FDA citing GPP as a rare orphan disease with significant unmet need; says potential FDA approval due as early as mid-2026

VNDA stock up 30% YTD, as of last close